Sign In
Buy DTIL
$6.04
-0.280 (-4.43%)
At Close: Jun 03, 2026
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies f
Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants
06:30am, Friday, 01'st Mar 2024
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene e
Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants
04:01pm, Thursday, 29'th Feb 2024
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene e
Strength Seen in Precision BioSciences (DTIL): Can Its 20.4% Jump Turn into More Strength?
05:26am, Tuesday, 27'th Feb 2024
Precision BioSciences (DTIL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strengt
Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences
07:00am, Tuesday, 20'th Feb 2024
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies f
Precision BioSciences to Present at Hep-DART 2023
07:00am, Thursday, 30'th Nov 2023
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies f
Precision BioSciences to Present at Upcoming H.C. Wainwright 4th Annual Hepatitis B Virus Conference
07:00am, Monday, 23'rd Oct 2023
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies fo
After Plunging -27.45% in 4 Weeks, Here's Why the Trend Might Reverse for Precision BioSciences (DTIL)
11:05am, Friday, 18'th Aug 2023
The heavy selling pressure might have exhausted for Precision BioSciences (DTIL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Stre
Precision BioSciences (DTIL) Reports Q2 Loss, Tops Revenue Estimates
09:47am, Friday, 04'th Aug 2023
Precision BioSciences (DTIL) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.44 per share a year ago.
Precision BioSciences to Report Second Quarter Results on August 4, 2023
05:00pm, Tuesday, 01'st Aug 2023
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, t
Precision Biosciences: Plenty Of Positive Updates; Waiting For The Market To Notice
07:27pm, Monday, 24'th Jul 2023
Precision Biosciences has been on a roll with positive updates in both their CAR T-Cell and gene editing pipelines. Unfortunately, the market has yet to recognize the positive updates. The company has
3 Penny Stocks to Catapult You Into the Millionaires' Club
01:03pm, Thursday, 13'th Jul 2023
Tech companies in certain high-growth sectors like semiconductors, AI, and cloud predominantly drove this year's bull market. But while these giants made headlines, many penny stocks continued trading
Precision BioSciences to Present at Upcoming June Investor Conferences
07:00am, Monday, 05'th Jun 2023
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, to
Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates
09:57am, Tuesday, 09'th May 2023
Precision BioSciences (DTIL) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.46 per share a year ago.
Precision BioSciences (DTIL) Reports Q4 Loss, Tops Revenue Estimates
09:53am, Thursday, 09'th Mar 2023
Precision BioSciences (DTIL) delivered earnings and revenue surprises of -8.33% and 78%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
